Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,

Slides:



Advertisements
Similar presentations
The Role of Government in Encouraging a High Standard of Ethics in the Healthcare Sector: Indonesia Experience Prof. Agus Purwadianto Senior Adviser to.
Advertisements

Introduction to Existing State Disclosure Laws and Regulations Summit on Disclosure, Transparency and Aggregate Spend For Drug, Device and Biotech Companies.
Professional Education Support Wyeth Pharmaceuticals Melinda Somasekhar, PhD.
PwC Medical Device Compliance Survey Discussion of Survey Results.
Pharmaceutical and Medical Device Manufacturer Conduct Melissa J. Lopes, Deputy General Counsel Massachusetts Department of Public Health.
Continuing Professional Development Conflict of Interest This presentation has been developed by the COI Working Group to assist in the implementation.
European Union of Medical Specialists November 18, 2011 Conference John McLoughlin Chairman, European Medical Technology Industry Association (EUCOMED)
Marketing to Doctors – Payments for Loyalty Julie Brill Assistant Attorney General Vermont Attorney General ’ s Office Montpelier,
Pharmaceutical Compliance Congress: “State of the States” October 27, 2008 Janice G. Cunningham Jeffrey L. Handwerker.
1 Physician-Industry Transparency: The U.S. Physician Payment Sunshine Act.
Sales & Marketing Compliance Training
Medicare Parts C and D Fraud, Waste, and Abuse Compliance Training
Compliance Requirements for the Pharmaceutical Industry and Impact on Marketing Practices Timothy M. Cunniff, Pharm.D. Vice President, Global Regulatory.
CORPORATE COMPLIANCE OVERVIEW David Meisels OSB Corporate Counsel Roundtable April 26, 2012.
ADVANCING HEALTHCARE THROUGH INNOVATIVE TECHNOLOGIES AND DEVICES ASSURER DE MEILLEURS SOINS DE SANTÉ GRÂCE À DES TECHNOLOGIES ET DES DISPOSITIFS.
The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Compliance Best Practices in a Post Orthopedic Environment David Matyas.
August, 2005 Slide 1 MANAGING RISKS OF OFF-LABEL PROMOTION AND CONTINUING MEDICAL EDUCATION The FDA Regulatory and Compliance Symposium Annenberg Hall.
# Operating Under the New Compliance Environment: Considerations for the Pharmaceutical Industry The Impact of the new Medicare Prescription Drug benefit.
© 2009 The McGraw-Hill Companies, Inc. All rights reserved. 1 McGraw-Hill Chapter 5 HIPAA Enforcement HIPAA for Allied Health Careers.
Introductory training Medical Technology Industry Code of Practice.
VCU School of Medicine Policy on Industry Relations Effective July 1, 2009.
Implementation of Disclosure Legislation in Massachusetts National Disclosure Summit March 6, 2009 Allan Coukell, Director of Policy.
Pharmaceutical, Biotech and Device Colloquium Princeton, New Jersey June 6-9, 2004 Medical Device Compliance Roundtable Medical Device Compliance Roundtable.
CORPORATE COMPLIANCE Tim Timmons Vice President Compliance and Regulatory Services Health Future, LLC.
OIG COMPLIANCE GUIDANCE FOR PHYSICIAN PRACTICES Washington County Hospital Association, Inc. CME Program October 26, 2000.
© 2008 Foley Hoag LLP. All Rights Reserved. 1 The New Massachusetts Pharmaceutical & Medical Device Marketing Regulations How to Address and Overcome Likely.
Blue Cross of Idaho Medicare Advantage Provider Fraud, Waste and Abuse Training Fall 2009.
How to Develop Internal Monitoring Programs SEVENTH ANNUAL PHARMACEUTICAL REGULATORY AND COMPLIANCE CONGRESS AND BEST PRACTICES FORUM Stephen F. Mohr Global.
Pitfalls and Lessons Learned: Advanced Implementation Strategies for a Compliant Grant Process National CME Audioconference December 9, 2008.
1 Strategies for a Compliant Grant Process CIA Monitoring Obligations A. Monica Jonhart Director-U S Pharmaceuticals Compliance Bristol-Myers Squibb.
1 Pharmaceutical and Medical Device Manufacturer Conduct Melissa J. Lopes, Deputy General Counsel Massachusetts Department of Public Health PHC Meeting.
Research Conflicts of Interest: Identifying and Minimizing COI from the Perspective of Faculty July 30, 2009 PonJola Coney, MD Senior Associate Dean for.
Pharmaceutical Compliance Congress Washington, DC June 9, 2003 The HHS OIG Guidance: An In-Depth Analysis of Risk Areas Panelists: Patrick Davish, Merck.
Vendor Relations Policy. Why Is There A Policy? The Patient Protection and Affordable Care Act was signed into law March 23, The new law contains.
+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.
A Focus on CME and Grants Nancy Coddington, PhD Senior Director, Compliance Operations AstraZeneca Pharmaceuticals LP And Terry Hisey Deputy Managing Principal.
The Ninth Annual Pharmaceutical Regulatory Compliance Congress and Best Practices Forum Thomas E. Costa Bristol-Myers Squibb Company This presentation.
+ Role of Industry in Clinical Care, Research, and Education.
Partners Conflict of Interest Policy and Reporting October 11, 2012.
An Educational Session on HSC OP 10.27, Health Care Vendor Interactions April 20, 2009.
1 Continuing Medical Education and Industry Sponsorship The Pharma, Biotech and Device Colloquium Princeton, NJ June 7, 2005 Julie K. Taitsman, M.D., J.D.
1 Harvard University Cambridge, MA March 29, 2007 Medical Device Congress AdvaMed’s Efforts to Promote Compliance Christopher L. White, Esq. Executive.
COCIR Code of Conduct Nicole DENJOY COCIR Secretary General.
Pwc Fifth Annual National Congress on Health Care Compliance Pharmaceutical Sales and Marketing: Are You Afraid to Look Under the Rocks? Michael P. Swiatocha.
Session 1.01 US Healthcare Professionals Abroad – Issues and Practical Solutions Caroline West – Senior VP, Chief Compliance and Risk Officer Shire Pharmaceuticals.
1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.
ROPES & GRAY LLP The Compliance Environment and Grant Process: Oversight and Response in the Pharmaceutical Industry Howard L. Dorfman December 9, 2008.
Lilly Answers that Matter. Preserving the Value of Industry Interactions with Health Care Professionals Jack Harris, M.D. Vice President, U.S. Medical.
California’s New Compliance Law Kelly N. Reeves
Japan Fair Competition Code for Medical Devices Industry (JFCC-MDI)
Compliance Issues in Dealing With Drug and Device Manufacturers Presentation to The Sixth Annual National Congress On Health Care Compliance Paul E. Kalb,
FDA Regulatory and Compliance Symposium Industry Collaboration & Interactions with Health Professionals: Can Conflicts of Interest be Properly Managed?
0 Due Diligence Monitoring and Auditing of Third Party Vendors October 28, 2008 Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum.
1 Global Codes of Ethics/Conduct Roundtable Discussion International Medical Device Compliance Congress and Best Practices Forum May 27, 2008 Paris Christopher.
Disclosure of Financial Interest Policy. Medical Staff Policy Approved by the MEC’s Aimed at protecting the integrity of the LMHS Medical Staffs Requires.
The IVD Australia Code of Conduct Edition 2.1
How to Apply for and Receive Industry Funding for Investigator Sponsored Research Chuck Simonton MD, FACC, FSCAI Chief Medical Officer Abbott Vascular.
Tamara V. Scoville, Esq. Reed Smith LLP
Complying with FDA/OIG Rules
PHARMA AUDIOCONFERENCE An Analysis of the HHS OIG Draft Compliance Program Guidance for the Pharmaceutical Industry Overview of Draft CPG Michael P.
University of Pittsburgh
The Most Important Element to Assure That Your Sales and Marketing Compliance Program is Working Effectively: Monitoring and Auditing Kelly B. Freeman,
2017 College of Medicine Compliance & Privacy R
Risk Management: why and how to protect your health center
California’s “Comprehensive Compliance Program” Law
Industry Induction Course
Updates to the PhRMA Code on Interactions with Healthcare Professionals National Pharma Audioconference August 5, 2008.
Coalition Sample Code of Ethics
Benchmarking Compliance for the Healthcare Industry
Implementing Controls Around Grants, Consulting Agreements, CME, Preceptorships, and Other Promotional Practices Paul E. Kalb Heidi C. Chen Fourth Annual.
Presentation transcript:

Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley, Esq. January 23, 2009

Voluntary Codes AdvaMed PhRMA OIG AMA

AdvaMed Code of Ethics on Interactions with Health Care Professionals Updated code approved by Board in December 2008 Takes effect on July 1, 2009 Target audience is all companies, not only AdvaMed members Health Care Professionals are individuals or entities involved in provision of health care services and/or items to patients, which purchase, lease, recommend, use, arrange for the purchase or lease of or prescribe a company’s medical technology

AdvaMed Compliance Program Annual certification to AdvaMed signed by CEO and COO Published on AdvaMed web site

AdvaMed Seven Elements of Effective Compliance Programs Written policies and procedures Compliance officer and committee Effective training and education Effective lines of communication Internal monitoring and auditing Enforcement through publicized disciplinary guidelines Prompt responses and corrective actions

AdvaMed Support of Third-Party Educational Conferences Permissible support for bona fide independent conferences –Grants –Meals and Refreshments –Faculty Expenses –Advertisements and Demonstration Sales, promotional and other business meetings –Bona fide professional interest in information –Appropriate location –Reasonable travel costs –Modest meals and refreshments

AdvaMed Consulting Arrangements Bona fide services for which legitimate need Written agreement –description of services –fair market value Limited input from sales personnel Royalty payments –not tied to use or promotion of product

AdvaMed Other Activities Entertainment and recreation Modest meals –permitted on and off-site depending on circumstances Research and educational grants and charitable donations –develop objective criteria for donations –not controlled by sales personnel Evaluation and demonstration products

AdvaMed Educational items; Prohibition on Gifts –strict prohibition on non-educational gifts (branded or unbranded) –permits items that benefit patients or have educational function if value < $100 –textbooks and anatomical models exempted from $100 cap

AdvaMed Code B D6CE347585/0/AdvaMedCodeofEthicsRevisedandRestatedEffe ctive pdf

PhRMA Code on Interactions with Healthcare Professionals Effective January 1, 2009 –Separate code on conduct of clinical trials and communication of clinical trial results –Target audience - all companies that interact with healthcare professionals about pharmaceuticals Encourages public commitment to abide by Code –Annual certification signed by CEO and CCO –Listed on PhRMA web site

PhRMA Support for CME and Educational Meetings Bona fide independent educational program Develop objective criteria No marketing or sales department involvement Provide $$ to meeting sponsor not healthcare professional No company involvement in program content or choice of speakers No logistic support for non-faculty healthcare professionals

PhRMA Educational Items Permitted if primarily for education of patients or healthcare professionals and cost < $100 May not have independent value outside professional responsibilities Offered only occasionally Consulting arrangements Bona fide arrangement Company records regarding appropriate use of services Venues of meetings conducive to consulting services- no recreational or entertainment events

PhRMA Other Informational Presentations Presentation of scientific and clinical information Modest meals In-house only if sales presentation Appropriate setting Prohibited gifts –Entertainment or recreational items of any value

PhRMA Code pdf

Office of the Inspector General (OIG) Compliance Program Guidance for Pharmaceutical Manufacturers Issued April 2003 Target audience is drug and biologics companies Encourages development and implementation of written compliance program Related to anti-kickback statute Areas of Potential Risk –Educational Grants Separate grant-making and sales/marketing functions –Research Funding

OIG Kickbacks and Other Illegal Remuneration Gifts and Entertainment Cites PhRMA Code (2002 version) –Adherence could reduce risk of fraud and abuse by demonstrating a good faith effort to comply

OIG Relationships with Physicians Personal Service Safe Harbor –Written signed agreement –Description of services –Specific payment arrangements –Legitimate need –Services actually provided –Fair market value

OIG Guidance 03pharmacymfgnonfr.pdf

American Medical Association (AMA) Ethical Guidelines for Gifts to Physicians from Industry Target audience is physicians Purpose is education Permits gifts that benefit patients and are of modest value Permits individual gifts that relate to physician’s work Physicians should not accept meeting-related payments directly from industry

AMA Permits faculty at conference to accept reasonable honoraria and logistical support Payments for bona fide consulting services permitted Student/intern/resident beneficiaries of conference grants chosen by academic institution Prohibits gifts with “strings attached”

AMA Code

Linda D. Bentley, Esq. Mintz Levin Cohn Ferris Glovsky and Popeo, P.C. One Financial Center Boston, MA (617)